Most pathogens are opportunistic and rely on quorum sensing, the cell-to-cell signaling that delays toxin production until the pathogens reach a population that can overcome host defenses. Plants immediately respond to toxins by “self-sacrificing” surrounding cells (Effector Triggered Immunity), converting polyphenols into molecules that aggressively bind to any proteins and other cell materials to contain the infection and disrupts quorum sensing.
EpiQuell’s patented pro-drug platform generates these same protein-reactive molecules when catalyzed by enzymes concentrated at sites of infection-compromised human tissues. EpiQuell treats infection without the side effects or resistance issues of antibiotics.
Our lead investigational drug, EPQ-100 has proven to be exceptionally safe and has demonstrated strong in-vitro inhibition of both Gram-negative and Gram-positive multi-drug resistant pathogens of primary concern to hospital systems. EPQ-100 is advancing into Phase II clinical trials against Clostridium difficile infection in 2018.